Project description:The deregulation of histone methylation profiles has been implicated in the pathogenesis of multiple diseases, including ovarian cancer, on of the most lethal gynaecological malignancies worldwide. The roles of de-methylases KDM6A/UTX and KDM6B/JDMJD3, generally associated with the maintenance of normal levels of H3K27 methylation, have not been investigated in detail in ovarian cancer, and their functions remain largely unknown. Here, we used the KDM6A/B targeting drug GSK-J4 to understand the implications of specific histone methylation in ovarian cancer. GSK-J4 triggered different responses including anti-proliferative activity, enhanced apoptotic cell death mechanisms and EMT differentiation, amongst others.
